Cargando…

Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schnell, Oliver, Battelino, Tadej, Bergenstal, Richard, Blüher, Matthias, Böhm, Michael, Brosius, Frank, Carr, Richard D., Ceriello, Antonio, Forst, Thomas, Giorgino, Francesco, Guerci, Bruno, Heerspink, Hiddo J. L., Itzhak, Baruch, Ji, Linong, Kosiborod, Mikhail, Lalić, Nebojša, Lehrke, Michael, Marx, Nikolaus, Nauck, Michael, Rodbard, Helena W., Rosano, Giuseppe M. C., Rossing, Peter, Rydén, Lars, Santilli, Francesca, Schumm-Draeger, Petra-Maria, Vandvik, Per Olav, Vilsbøll, Tina, Wanner, Christoph, Wysham, Carol, Standl, Eberhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990484/ https://www.ncbi.nlm.nih.gov/pubmed/35395808 http://dx.doi.org/10.1186/s12933-022-01481-0

Ejemplares similares

Report from the 5th cardiovascular outcome trial (CVOT) summit
por: Schnell, Oliver, et al.
Publicado: (2020)

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
por: Schnell, Oliver, et al.
Publicado: (2023)

Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
por: Schnell, Oliver, et al.
Publicado: (2021)

Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop
por: Ceriello, Antonio, et al.
Publicado: (2023)

Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2018)

Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2016)

Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2019)

Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2017)

Correction to: Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2017)

Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
por: Blüher, Matthias, et al.
Publicado: (2022)

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs
por: Schernthaner, Guntram, et al.
Publicado: (2019)

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

Current perspectives on cardiovascular outcome trials in diabetes
por: Schnell, Oliver, et al.
Publicado: (2016)

Correction to: Updates on cardiovascular outcome trials in diabetes
por: Schnell, Oliver, et al.
Publicado: (2017)

Updates on cardiovascular outcome trials in diabetes
por: Schnell, Oliver, et al.
Publicado: (2017)

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2021)

Issues for the management of people with diabetes and COVID-19 in ICU
por: Ceriello, Antonio, et al.
Publicado: (2020)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Cardiovascular Profile of Patients with Type 2 Diabetes in France Based on REWIND CVOT Inclusion Criteria: A Real-World Retrospective Study
por: Dib, Anne, et al.
Publicado: (2022)

Postprandial Hyperglycemia and Glycemic Variability: Should we care?
por: Standl, Eberhard, et al.
Publicado: (2011)

Fragility of cardiovascular outcome trials (CVOTs) examining nutrition interventions among patients with diabetes mellitus: a systematic review of randomized controlled trials
por: Taouktsi, Niki, et al.
Publicado: (2022)

Incretin-Based Therapies: Viewpoints on the way to consensus
por: Nauck, Michael. A., et al.
Publicado: (2009)

Long COVID — metabolic risk factors and novel therapeutic management
por: Khunti, Kamlesh, et al.
Publicado: (2021)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes
por: Schnell, Oliver, et al.
Publicado: (2020)

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
por: Nauck, Michael, et al.
Publicado: (2014)

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care 2014;37:2149–2158
por: Nauck, Michael, et al.
Publicado: (2015)

Treating diabetic complications; from large randomized clinical trials to precision medicine
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy
por: de Zeeuw, Dick, et al.
Publicado: (2020)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
por: Wysham, C, et al.
Publicado: (2011)

Renal outcomes and all‐cause death associated with sodium‐glucose co‐transporter‐2 inhibitors versus other glucose‐lowering drugs (CVD‐REAL 3 Korea)
por: Koh, Eun Sil, et al.
Publicado: (2020)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
por: Ceriello, Antonio, et al.
Publicado: (2021)

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease
por: Pena, Michelle J., et al.
Publicado: (2016)

Exposure–response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials
por: Koomen, Jeroen V., et al.
Publicado: (2020)

Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qt3kknn3vi8ll7q5n7m6mn0dc3